Clinical trial Recruiting at 1 site Interventional Ages 18 to 65

Preventing agitation after rhinoplasty with low-dose propofol or single-dose dexmedetomidine

Official title: Van Yuzuncu Yil University Faculty of Medicine Ethics Committee

Run by Yuzuncu Yil University · NCT07144007 · Data updated 2026-11-12

This will test whether giving either a low dose of propofol or a single dose of dexmedetomidine at the end of anesthesia reduces emergence agitation in adults having elective rhinoplasty.

More Emergence Agitation trials

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment80 (estimated)
SponsorYuzuncu Yil University
Academic / other
Locations1 site (Van, Tuşba)
StatusRecruiting
StartedApril 15, 2025
Main results expectedJanuary 1, 2026
Study endsFebruary 1, 2026
Registry record updatedAugust 27, 2025
Trial IDNCT07144007 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–65 years with ASA physical status I–II who are scheduled for elective rhinoplasty and have no significant organ disease or known allergy to the study drugs are ideal candidates.

Probably not a fit

Patients outside the 18–65 age range, those with ASA III or higher, significant renal/hepatic/cardiac/respiratory disease, known allergies to the medications, or not undergoing rhinoplasty are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, double-blind study will enroll 80 adults aged 18–65 years with ASA I–II scheduled for elective rhinoplasty and assign 40 patients to a subanesthetic propofol group and 40 to a single-dose dexmedetomidine group. All patients will receive standardized general anesthesia and, after nasal tampon placement, one group will receive 0.5 mg/kg propofol while the other receives 0.5 mcg/kg dexmedetomidine infused over 10 minutes. Patients will be extubated when they breathe spontaneously and open their eyes to verbal stimulation, and agitation will be measured with the Richmond Agitation Sedation Scale one minute after extubation while vitals are monitored. The main comparison is the rate and severity of emergence agitation between the two groups.

Why it matters

Potential benefit: If successful, this approach could reduce the frequency and severity of emergence agitation after rhinoplasty, improving patient comfort and recovery safety.

How similar studies have gone: Previous studies in other surgical settings have shown that dexmedetomidine and low-dose propofol can reduce emergence agitation, but direct head-to-head evidence specifically in rhinoplasty patients is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients scheduled for rhinoplasty
* Between 18-65 years
* ASA I-II group

Exclusion Criteria:

* Those who are outside the age range of 18-65
* Those who are ASA III and above
* Those with renal,hepatic, cardiac and respiratory diseases
* Those with a known allergy to the medication to be used
* Those who underwent urinary catheterization

Where it's running

  • Van Yüzüncü Yıl University
    Van, Tuşba, Turkey (Türkiye)
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.